4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Erasca, Inc. (ERAS) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 103 employees. Its market capitalization is roughly $6 billion. In the fiscal year ended 2025-12-31, ERAS reported $0M in revenue and ($124M) in net income.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($131M) | ($157M) | ($142M) | ($145M) | — |
| Net Income | ($124M) | ($162M) | ($125M) | ($243M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($38M) | ($33M) | ($32M) | ($31M) | ($36M) | — |
| Net Income | ($183M) | ($29M) | ($31M) | ($34M) | ($31M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $396M | $502M | $395M | $515M | — |
| Total Liabilities | $71M | $79M | $79M | $103M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ERAS viewer.
About TickerBase · Data methodology & sources